Table 4.
The in vivo activity of different formulations against L. donovani spleen, liver and bone marrow parasite burdens. L. donovani infected mice (n = 4 or 5) were treated with medium alone (intravenous route), miltefosine (Milt, oral), or APC12 (oral or intravenous route, IV) on day 7 post-infection and parasite burdens then assessed on day 14 post-infection. The mean percentage suppression ± SD in parasite burdens is shown in parentheses. *p < 0.05, ** p < 0.01 vs. control, a p < 0.05, b p < 0.01 MIL vs. APC12, c p < 0.05 APC12 40 vs. 80 mg/kg.
| Treatment | Mean Parasite Burden ± SD | ||
|---|---|---|---|
| Spleen | Liver | Bone Marrow | |
| Experiment 1: Oral administration | |||
| Control | 198 ± 62 | 1000 ± 286 | 225 ± 100 |
| MIL 40 mg/kg oral | 73 ± 68 * (53 ± 31) |
433 ± 46 ** (40 ± 25) |
197 ± 157 (30 ± 35) |
| APC12 40 mg/kg oral | 275 ± 96 b (8 ± 18) |
880 ± 276 a (36 ± 34) |
210 ± 90 (54 ± 34) |
| Experiment 2: Intravenous administration | |||
| Control | 305 ± 97 | 1299 ± 158 | 458 ± 129 |
| APC12 40 mg/kg IV | 112 ± 30 * (60 ± 11) |
434 ± 197 ** (60 ± 19) |
555 ± 254 (8 ± 14) |
| APC12 80 mg/kg oral | 257 ± 73 c (13 ± 27) |
939 ± 170 c (27 ± 16) |
607 ± 115 (2 ± 4) |